Effect of sarpogrelate on angiographic luminal loss and clinical outcome after endovascular treatment for peripheral artery disease

Not Applicable

Conditions: Diseases of the circulatory system

Registration Number: KCT0004511

Lead Sponsor: Dong-A University Hospital

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot yet recruiting

Sex: All

Target Recruitment: 50

Inclusion Criteria

1. Patients with a newborn femoral artery lesion or a newborn knee-well (BTK) lesion with a greater than 50% stenosis;
2. Successful completion of peripheral vascular (PTA) treatment with peripheral arterial vessels (Fontaine 2, 3) or severe inferior ischemia (CLI)
3. Patients with at least 3 months of treatment after peripheral vascular treatment of antipsychotic - like aspirin + clopidogrel

Exclusion Criteria

1. Under 18; over 85; over 85.
2. For lesions of incoming arteries: Inflow lesion: aortoilliac arterial lesion
3. In case of acute limb ischemia by thrombus
4. In the case of taboos in administering anti-platelet drugs and with thrombocytopenia (<100,000/µL)
5. Patient with liver cirrhosis of Child Class B and higher
6. Patients with anticoagulants
7. Severe heart failure (with a heart rate of less than 35% or NYHA 4)
8. If you have recently developed cerebral infarction or myocardial infarction (within 6 months)
9. Patients whose life expectancy is expected to be less than one year due to other conditions
10. Pregnant women, pregnant or nursing mothers

Study & Design

Study Type: Interventional Study

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
te luminal loss relative to baseline (peripheral angiography taken immediately after PTA procedure). Evaluation item: Peripheral angiography;?Resenosis evaluation compared to baseline (peripheral angiography taken immediately after PTA procedure).?Evaluation item: ABI evaluation compared to Peripheral angiography (SV/V1) ?SF36 evaluation compared to Baseline (SV)

Secondary Outcome Measures

Name	Time	Method
?major adverse cardiovascular event, MACE-death, myocardial infarction, cerebral infarction, and resection of peripheral blood vessels?TIMI critia?CBC (Check red blood cells, platelet numbers)